XORTX Therapeutics (XRTX) Net Margin (2023)

XORTX Therapeutics' (XRTX) quarterly Net Margin came in at 140.09% in Q3 2023, down 40.09% on a QoQ basis from 100.0% in Q2 2023.

XORTX Therapeutics (XRTX) Net Margin (2023) Analysis & Trends

XORTX Therapeutics (XRTX) has 1 years of Net Margin data on file, last reported at 140.09% in Q3 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Margin (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	32.99%
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	30.23%
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	31.16%
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-539.31%
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	13.90%
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	12.74%
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	-3.12%
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	12.09%
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	-16.51%
10	XORTX Therapeutics	2.78 Mn	2.78 Mn	-	-

Download Data